3|1|Public
50|$|<b>Fasoracetam</b> is a {{research}} chemical of the racetam family. It is a nootropic, {{and has been in}} clinical trials for vascular dementia and attention deficit hyperactivity disorder.|$|E
50|$|<b>Fasoracetam</b> {{appears to}} agonize all three metabotropic {{glutamate}} receptors and has improved cognitive function in rodent studies. It is orally available and is excreted mostly unchanged via the urine.|$|E
50|$|<b>Fasoracetam</b> was {{discovered}} by scientists at the Japanese pharmaceutical company Nippon Shinyaku, which brought it through Phase 3 clinical trials for vascular dementia, and abandoned it {{due to lack of}} efficacy.|$|E
5000|$|Scientists at Children's Hospital of Philadelphia led by Hakon Hakonarson {{identified}} <b>fasoracetam's</b> potential use in {{attention deficit}} hyperactivity disorder. Hakonarson started a company called neuroFix Therapeutics, LLC {{to try to bring}} the drug to market for this use; neuroFix acquired Nippon Shinyaku's clinical data as part of its efforts. [...] neuroFix was acquired by Medgenics in 2015. [...] Medgenics changed its name to Aevi Genomic Medicine in 2016. [...] Clinical trials in adolescents with ADHD who also have mGluR mutations started in 2016.|$|R

